857890-39-2 | Lenvatinib mesylate

Packsize	Purity	Availability	Price	Discounted Price
25mg	97%	in stock	$45.00	$32.00
1g	97%	in stock	$66.00	$47.00
5g	97%	in stock	$171.00	$120.00
10g	97%	in stock	$299.00	$209.00
25g	97%	in stock	$573.00	$402.00

Description

• Catalog Number: AH50958
• Chemical Name: Lenvatinib mesylate
• CAS Number: 857890-39-2
• Molecular Formula: C22H23ClN4O7S
• Molecular Weight: 522.9586
• MDL Number: MFCD18633219
• SMILES: CS(=O)(=O)O.COc1cc2nccc(c2cc1C(=O)N)Oc1ccc(c(c1)Cl)NC(=O)NC1CC1

Computed Properties

• Complexity: 727
• Covalently-Bonded Unit Count: 2
• Heavy Atom Count: 35
• Hydrogen Bond Acceptor Count: 8
• Hydrogen Bond Donor Count: 4
• Rotatable Bond Count: 6

Literature

• Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.

  Lancet (London, England) 20180324

• Lenvatinib: first global approval.

  Drugs 20150401

• A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours.

  British journal of cancer 20120508

• Novel molecular targeted therapies for refractory thyroid cancer.

  Head & neck 20120501

• Unique metabolic pathway of [(14)C]lenvatinib after oral administration to male cynomolgus monkey.

  Drug metabolism and disposition: the biological fate of chemicals 20120401

• Development and validation of LC-MS/MS assays for the quantification of E7080 and metabolites in various human biological matrices.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20120301

• Antitumour activity of oral E7080, a novel inhibitor of multiple tyrosine kinases, in human sarcoma xenografts.

  International journal of cancer 20110801

• E7080 suppresses hematogenous multiple organ metastases of lung cancer cells with nonmutated epidermal growth factor receptor.

  Molecular cancer therapeutics 20110701

• Phase I dose-escalation study and biomarker analysis of E7080 in patients with advanced solid tumors.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20110415

• Antiangiogenic therapies for malignant pleural mesothelioma.

  Frontiers in bioscience (Landmark edition) 20110101

• E7080, a multi-targeted tyrosine kinase inhibitor suppresses tumor cell migration and invasion.

  BMC cancer 20110101

• A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080.

  Journal of pharmacokinetics and pharmacodynamics 20100801

• E7080, a multi-tyrosine kinase inhibitor, suppresses the progression of malignant pleural mesothelioma with different proangiogenic cytokine production profiles.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20091201

• Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20080901

• E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition.

  International journal of cancer 20080201